Hidradenitis suppurativa

The PBS subsidises biological medicines for patients with moderate to severe hidradenitis suppurativa.

Patient eligibility

The Pharmaceutical Benefits Scheme (PBS) subsidises treatment with biological medicines under the National Health Act 1953, section 85 for patients with moderate to severe hidradenitis suppurativa.

Where the term biological medicine appears, it refers to:

  • adalimumab
  • bimekizumab
  • secukinumab

Patients must be eligible for the PBS and meet the relevant restriction criteria.

The Schedule of Pharmaceutical Benefits on the PBS website outlines the restrictions for prescribing biological medicines.

Treatment specifics

To be eligible for PBS-subsidised treatment with biological medicines, patients must be treated by a dermatologist.

Authority applications

Applying for initial, change or recommencement of treatment

Please note: You don’t need to complete this application in writing when you request PBS authority online.

Applications for initial, change or recommencement authority approval to prescribe PBS-subsidised biological medicines to treat moderate to severe hidradenitis suppurativa can be made:

All written applications must include:

Applying for initial grandfather treatment

Please note: You don’t need to complete this application in writing when you request PBS authority online.

Applications for initial grandfather authority approval to prescribe PBS-subsidised bimekizumab to treat moderate to severe hidradenitis suppurativa can be made:

All written applications must include:

Applying for continuing treatment

Please note: You’ll get an immediate assessment when you request PBS authorities online.

Applications for continuing authority approval to prescribe PBS-subsidised biological medicines to treat moderate to severe hidradenitis suppurativa can be made in:

All written applications must include:

After we approve the first application for continuing treatment with adalimumab, subsequent continuing treatments with PBS-subsidised biosimilar brands of adalimumab are Authority Required (Streamlined). You don’t need authority approval from us for the listed quantity and repeats.

More information

Call the PBS Complex Drugs Programs enquiry line for more information.

Page last updated: 1 December 2025.
QC 37831